BRIEF-AIM Immunotech Signs Agreement For Planning Of A Proposed Phase 3 Clinical Trial Of Ampligen In The Treatment Of Late-Stage Pancreatic Cancer

Reuters
Yesterday
BRIEF-AIM Immunotech Signs Agreement For Planning Of A Proposed Phase 3 Clinical Trial Of Ampligen In The Treatment Of Late-Stage Pancreatic Cancer

March 2 (Reuters) - AIM ImmunoTech Inc AIM.A:

  • AIM IMMUNOTECH SIGNS AGREEMENT FOR PLANNING OF A PROPOSED PHASE 3 CLINICAL TRIAL OF AMPLIGEN IN THE TREATMENT OF LATE-STAGE PANCREATIC CANCER

  • AIM IMMUNOTECH INC - SIGNS AGREEMENT WITH THERMO FISHER FOR PHASE 3 TRIAL OF AMPLIGEN

Source text: ID:nGNXzn7Pq

Further company coverage: AIM.A

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10